The amount of aggregate consideration for equity investment.

No definition available.

Name:	casi_AggregateConsiderationForEquityInvestment
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the percentage of equity held in joint venture.

+ References

No definition available.

+ Details

Name:	casi_PercentageOfEquityHeldInJointVenture
Namespace Prefix:	casi_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents percentage of interest in board seats.

+ References

No definition available.

+ Details

Name:	casi_PercentageOfInterestInBoardSeats
Namespace Prefix:	casi_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The increase (decrease), resulting in a loss, that was included in earnings for the period.

+ References

No definition available.

+ Details

Name:	casi_UnrealizedLoss
Namespace Prefix:	casi_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Name:	us-gaap_EquitySecuritiesFvNiRealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713

+ Details

Name:	us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of unrealized gain (loss) on investment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_UnrealizedGainLossOnInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_BioinventInternationalAbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	casi_InvestmentsContractCounterpartyAxis=casi_PrecisionAutoimmuneTherapeuticsCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=casi_CasiPharmaceuticalsChinaCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=casi_GuangzhouRedhillCapitalInvestmentManagementCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=casi_WuxiZhiheDaukangPhaseIiVentureCapitalPartnershipMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=casi_HainanJingshiKangjiPharmaceuticalsTechnologyPartnershipMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Investment in Equity Securities, at Fair Value and Long-term Investments (Details) € in Millions, ¥ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2022 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	May 31, 2022 EUR (€)	May 31, 2022 CNY (¥)
Unrealized gain (losses) on equity investment		$ 0	$ 1,900,000	$ 0	$ 3,400,000
Unrealized losses		$ 1,400,000	$ 0	$ 3,000,000.0	$ 0
BioInvent International AB \| Common Stock
Number of ordinary shares sold \| shares		275,000
Proceed from sale of equity securities		$ 1,300,000
Gain on equity securities		$ 131,000
Precision Autoimmune Therapeutics Co., Ltd
Percentage of interest in board seats	33.33%
Aggregate consideration for equity investment	$ 3,000,000.0					€ 20.0	¥ 20.0
Precision Autoimmune Therapeutics Co., Ltd \| CASI (China)
Percentage of equity held in joint venture	15.00%
Precision Autoimmune Therapeutics Co., Ltd \| Guangzhou Redhill Capital Investment Management Co., Ltd
Equity ownership (as a percent)	27.50%					27.50%	27.50%
Precision Autoimmune Therapeutics Co., Ltd \| Wuxi Zhihe Daukang Phase II Venture Capital Partnership
Equity ownership (as a percent)	27.50%					27.50%	27.50%
Precision Autoimmune Therapeutics Co., Ltd \| Hainan Jingshi Kangji Pharmaceuticals Technology Partnership
Equity ownership (as a percent)	30.00%					30.00%	30.00%